



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John D. PLUENNEKE

Serial No.: 10/712,122

Group Art Unit No.: 1614

Filed: November 13, 2003

Examiner: Unknown

For: METHODS OF TREATMENT USING AN INHIBITOR OF EPIDERMAL
GROWTH FACTOR RECEPTOR

Docket No.: 3369-A

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. 37 CFR 1.97(b).

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 09-0089 in the name of Immunex Corporation.

Respectfully submitted,

Rosemary Sweeney
Attorney/Agent for Applicant
Registration No.: 52,264
Phone: (206) 265-7817
Date: May 28, 2004

Please send all future correspondence to:

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, WA 98119-3105
(206) 265-7000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

May 28, 2004
Date

Signature

Modified Form PTO-1449		Atty. Docket No. 3369-A	Serial No. 10/712.122
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Applicant John D. PLUENNEKE	
		Filing Date November 13, 2003	Group 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	2002/0001587	01/03/2002	Erickson et al.			
	A2	2002/0012663	01/31/2002	Waksal			
	A3	2002/0034736	03/21/2002	Falb et al.			
	A4	2002/0058033	05/16/2002	Raisch et al.			
	A5	2002/0065398	05/30/2002	del Rio et al.			
	A6	2002/0102685	08/01/2002	Sibilia et al.			
	A7	2002/0107284	08/08/2002	Uckun et al.			
	A8	5,183,805	02/02/1993	Lee et al.			
	A9	5,459,061	10/17/1995	Sato et al.			
	A10	5,558,864	09/24/1996	Bendig et al.			
	A11	5,770,195	06/23/1998	Hudziak			
	A12	5,844,093	12/01/1998	Kettleborough et al.			
	A13	5,874,528	02/23/1999	Lupu et al.			
	A14	5,891,996	04/06/1999	del Rio et al.			
	A15	5,894,018	04/13/1999	Davila et al.			
	A16	5,914,269	06/22/1999	Bennett et al.			
	A17	5,981,725	11/09/1999	Vogelstein et al.			
	A18	6,057,156	05/02/2000	Akhtar et al.			
	A19	6,127,344	10/03/2000	Amici et al.			
	A20	6,129,915	10/10/2000	Wels et al.			
	A21	6,187,585	02/13/2001	Bennett et al.			
	A22	6,217,866	04/17/2001	Schlessinger et al.			
	A23	6,224,868	05/01/2001	Wong et al.			
	A24	6,235,883	05/22/2001	Jakobovits et al.			

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Continued)	Atty. Docket No.	Serial No.
	3369-A	10/712.122
	Applicant	
	John D. PLUENNEKE	
	Filing Date	Group
	November 13, 2003	1614

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	B1	0 566 226 B1	11/08/1995	EP				
	B2	0 667 165 B1	03/27/2002	EP				
	B3	1 170 011 A1	01/09/2002	EP				
	B4	WO 95/20045	07/27/1995	PCT				
	B5	WO 95/24190	09/14/1995	PCT				
	B6	WO 96/30347	10/03/1996	PCT				
	B7	WO 96/40648	12/19/1996	PCT				
	B8	WO 97/41226	11/06/1997	PCT				
	B9							

EXAMINER'S
INITIALS**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

	C1	Boccardo F et al., "Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast," <i>Int J Cancer (Pred Oncol)</i> ; 95:260-265, 2001.
	C2	Ciardiello F and Tortora G, "A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor," <i>Clin Cancer Res</i> , 7:2958-2970, 2001.
	C3	Crombet-Ramos T et al., "Pharmacological and clinical evaluation of the humanized anti EGF-R monoclonal antibody, h-R3, in patients with advanced epithelial carcinomas," 2001 ASCO Annual Meeting, May 12-15, 2001, San Francisco, CA, Abstract No. 1012.
	C4	Di Lieto A et al., "EGF/EGF-R system and benign breast disease during and following the treatment of gynaecological pathologies with an analogue of LH-RH," <i>Clin Exp Obst Gyn</i> , XXIII(4):220-228, 1996.
	C5	Dorrance AM et al., "Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats," <i>Am J Physiol Regulatory Integrative Comp Physiol</i> , 281:R944-R950, 2001.
	C6	Heldin C-H, "Signal transduction: multiple pathways, multiple options for therapy," <i>Stem Cells</i> 19:295-303, 2001.
	C7	Hess JC et al., "Growth factor profiles in breast cyst fluid identify women with increased breast cancer risk," <i>Am J Surg</i> , 167:523-530, 1994.
	C8	Justicia C and Planas AM, "Transforming growth factor- α acting at the epidermal growth factor receptor reduces infarct volume after permanent middle cerebral artery occlusion in rats," <i>J Cereb Blood Flow Metab</i> , 19:128-132, 1999.
	C9	Miyazaki Y et al., "Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor," <i>Gastroenterology</i> , 116:78-89, 1999.

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449 LIST OF REFERENCES CITED BY APPLICANT (Continued)	Atty. Docket No.	3369-A	Serial No.	10/712.122
	Applicant			
	John D. PLUENNEKE			
	Filing Date	November 13, 2003	Group	1614

EXAMINER'S INITIALS		OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)
	C10	Nicholson RI et al., "EGFR and cancer prognosis," <i>Eur J Cancer</i> , 37:S9-S15, 2001.
	C11	Nishi E et al., "Lysophosphatidylcholine increases expression of heparin-binding epidermal growth factor-like growth factor in human T lymphocytes," <i>Circ Res</i> , 80:638-644, 1997.
	C12	Noble F et al., "International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors," <i>Pharmacol Rev</i> , 51(4):745-781, 1999.
	C13	Pavelic K et al., "Evidence for a role of EGF receptor in the progression of human lung carcinoma," <i>Anticancer Res</i> , 13:1133-1138, 1993.
	C14	Rozengurt E and Walsh JH, "Gastrin, CCK, signaling, and cancer," <i>Annu Rev Physiol</i> 63:49-76, 2001.
	C15	Sambhi MP et al., "Increased EGF binding and EGFR mRNA expression in rat aorta with chronic administration of pressor angiotensin II," <i>Biochem Med Metab Biol</i> , 48:8-18, 1992.
	C16	Schaer J-C and Reubi JC, "High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents," <i>J Clin Endocrinol Metab</i> , 84:233-239, 1999.
	C17	Shaw JP et al., "Cytotoxic properties of DAB ₄₈₆ EGF and DAB ₃₈₉ EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins," <i>J Biol Chem</i> , 266(31):21118-21124, 1991.
	C18	Smith AM et al., "Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer," <i>Clin Cancer Res</i> , 6:4719-4724, 2000.
	C19	Smith AM and Watson SA, "Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence," <i>Gut</i> , 47:820-824, 2000.
	C20	Swaminathan N et al., "Elevated epidermal growth factor receptor levels in hypertensive Lyon rat kidney and aorta," <i>Clin Exp Pharmacol Physiol</i> , 23:793-796, 1996.
	C21	Ullrich A et al., "Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells," <i>Nature</i> , 309:418-425, 1984.
	C22	Watson SA et al., "Transforming growth factor- α -mediated growth pathways in human gastro-intestinal cell lines in relation to the gastrin autocrine pathway," <i>Int J Cancer</i> , 87:20-28, 2000.
	C23	Zwick E et al., "Receptor tyrosine kinase signalling as a target for cancer intervention strategies," <i>Endocrine-Related Cancer</i> , 8:161-173, 2001.
	C24	
	C25	
	C26	

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	